

## ICMJE DISCLOSURE FORM

Date: 29 December 2021  
 Your Name: Arend Mosterd  
 Manuscript Title: "Hartfalen: nieuwe behandelmogelijkheden en het belang van de ejectiefractie."  
 Manuscript number (if known): \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.


In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	____ None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Unrestricted Research Grant from Novartis	Paid in full to Utrecht University Medical Center, dept. of Vascular Medicine.
3	Royalties or licenses	____ None	

4	Consulting fees	Amgen Astra Bayer Boehringer Ingelheim MSD Novartis	<ul style="list-style-type: none"> <li>- National Lead Victoria Study (Vericiguat, Bayer / MSD)</li> <li>- National Lead Paradigm Study (Sacubitril Valsartan, Novartis)</li> <li>- Consulting / lecture fees from Amgen, Astra, BI, and Novartis.</li> </ul> <p>Dr. Mosterd will not accept personal fees. Honoraria will be directed towards research funding.</p>
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.



A. MOSTERD 29/12-21.